Scynexis-Color.png
SCYNEXIS to Participate in Maxim Group’s Late Stage Innovations in Women’s Health Virtual Event
February 25, 2021 16:15 ET | Scynexis
JERSEY CITY, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
Scynexis-Color.png
SCYNEXIS and Amplity Health Announce Agreement to Support the Anticipated U.S. Commercialization of BrexafemmeTM (Ibrexafungerp) for Vaginal Yeast Infections
February 23, 2021 08:15 ET | Scynexis
Synergistic combination of Amplity’s proven commercial sales capabilities and SCYNEXIS’ internal medical, marketing, and strategic expertise will maximize Brexafemme’s commercial potential while...
Scynexis-Color.png
SCYNEXIS Announces Licensing Agreement and Strategic Partnership with Hansoh Pharma for Rights to Ibrexafungerp in Greater China
February 17, 2021 08:15 ET | Scynexis
Hansoh Pharma, one of the largest biopharmaceutical companies in Greater China and in Asia, provides fully integrated R&D, manufacturing, and commercial capabilities to accelerate entry of...
Scynexis-Color.png
SCYNEXIS Announces Closing of $85 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants
December 22, 2020 08:00 ET | Scynexis
JERSEY CITY, N.J., Dec. 22, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) today announced the closing of its previously announced underwritten public offering of common stock, pre-funded...
Scynexis-Color.png
SCYNEXIS Announces Pricing of $85 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants
December 17, 2020 09:29 ET | Scynexis
JERSEY CITY, N.J., Dec. 17, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the pricing of its underwritten public offering of common stock, pre-funded warrants and warrants....
Scynexis-Color.png
SCYNEXIS Announces Launch of $50 Million Public Offering of Common Stock and Warrants
December 16, 2020 16:21 ET | Scynexis
JERSEY CITY, N.J., Dec. 16, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that it has commenced an underwritten public offering of shares of its common stock and warrants to...
Scynexis-Color.png
SCYNEXIS Announces Advancement of Ibrexafungerp’s Intravenous Formulation to Clinical Stage and Provides Further Updates on its Clinical Studies in Patients with Life-Threatening Fungal Infections
December 10, 2020 08:00 ET | Scynexis
Approval granted by health authority for the intravenous (IV) formulation of ibrexafungerp to enter Phase 1; dosing in healthy volunteers to start in the first quarter of 2021 New interim analysis of...
Scynexis-Color.png
SCYNEXIS Announces FDA Acceptance and Priority Review of New Drug Application for Oral Ibrexafungerp for the Treatment of Vaginal Yeast Infections
December 07, 2020 08:00 ET | Scynexis
6-month Priority Review granted for ibrexafungerp with PDUFA target action date set for June 1, 2021 FDA indicated that it is not currently planning to hold an advisory committee meeting for the...
Scynexis-Color.png
SCYNEXIS to Participate in Piper Sandler and Evercore ISI Conferences
November 24, 2020 09:35 ET | Scynexis
JERSEY CITY, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
Scynexis-Color.png
SCYNEXIS Reports Third Quarter 2020 Financial Results and Provides Company Update
November 06, 2020 08:45 ET | Scynexis
In October, SCYNEXIS submitted a New Drug Application (NDA) for ibrexafungerp for the treatment of vulvovaginal candidiasis (VVC) with expected approval in mid-2021. SCYNEXIS estimates that there are...